Evidence map›Paper›PMID 24586613›Full record

ArticlePloS one2014

Inhibition of post-transcriptional RNA processing by CDK inhibitors and its implication in anti-viral therapy.

Jitka Holcakova, Petr Muller, Peter Tomasec, Roman Hrstka, Marta Nekulova, Vladimir Krystof, Miroslav Strnad, Gavin W G Wilkinson, Borivoj Vojtesek

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Cyclin-dependent kinase activity is required for type I interferon production.Proceedings of the National Academy of Sciences of the United States of America · 2018
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Jitka HolcakovaRegional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
Petr MullerRegional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
Peter TomasecSchool of Medicine, Cardiff University, Cardiff, United Kingdom.
Roman HrstkaRegional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
Marta NekulovaRegional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
Vladimir KrystofLaboratory of Growth Regulators, Faculty of Science, Palacky University, Olomouc, Czech Republic ; Institute of Experimental Botany AS CR, Olomouc, Czech Republic.
Miroslav StrnadLaboratory of Growth Regulators, Faculty of Science, Palacky University, Olomouc, Czech Republic ; Institute of Experimental Botany AS CR, Olomouc, Czech Republic.
Gavin W G WilkinsonSchool of Medicine, Cardiff University, Cardiff, United Kingdom.
Borivoj VojtesekRegional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
Masaryk Memorial Cancer Institute · CZCardiff University · GBCzech Academy of Sciences, Institute of Experimental Botany · CZPalacký University Olomouc · CZ

Funding

Medical Research Council G0700142Medical Research Council G1000236Medical Research Council MR/L018373/1
6 · The paper itself

Abstract

Cyclin-dependent kinases (CDKs) are key regulators of the cell cycle and RNA polymerase II mediated transcription. Several pharmacological CDK inhibitors are currently in clinical trials as potential cancer therapeutics and some of them also exhibit antiviral effects. Olomoucine II and roscovitine, purine-based inhibitors of CDKs, were described as effective antiviral agents that inhibit replication of a broad range of wild type human viruses. Olomoucine II and roscovitine show high selectivity for CDK7 and CDK9, with important functions in the regulation of RNA polymerase II transcription. RNA polymerase II is necessary for viral transcription and following replication in cells. We analyzed the effect of inhibition of CDKs by olomoucine II on gene expression from viral promoters and compared its effect to widely-used roscovitine. We found that both roscovitine and olomoucine II blocked the phosphorylation of RNA polymerase II C-terminal domain. However the repression of genes regulated by viral promoters was strongly dependent on gene localization. Both roscovitine and olomoucine II inhibited expression only when the viral promoter was not integrated into chromosomal DNA. In contrast, treatment of cells with genome-integrated viral promoters increased their expression even though there was decreased phosphorylation of the C-terminal domain of RNA polymerase II. To define the mechanism responsible for decreased gene expression after pharmacological CDK inhibitor treatment, the level of mRNA transcription from extrachromosomal DNA was determined. Interestingly, our results showed that inhibition of RNA polymerase II C-terminal domain phosphorylation increased the number of transcribed mRNAs. However, some of these mRNAs were truncated and lacked polyadenylation, which resulted in decreased translation. These results suggest that phosphorylation of RNA polymerase II C-terminal domain is critical for linking transcription and posttrancriptional processing of mRNA expressed from extrachromosomal DNA.

Indexed as

AnimalsCell CycleCell LineChlorocebus aethiopsCyclin-Dependent KinasesDNA, ViralHumansKidneyPhosphorylationPromoter Regions, GeneticProtein Kinase InhibitorsPurinesRNA Polymerase IIRNA Processing, Post-TranscriptionalRoscovitineCyclin-Dependent KinasesDNA, Viralolomoucine IIProtein Kinase InhibitorsPurinesRNA Polymerase IIRoscovitine

Identifiers

PMID24586613
PMCPMC3931720
OpenAlexW2026029674

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.